Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.78
USD
|
+1.71%
|
|
+2.89%
|
-22.61%
|
Fiscal Period: May |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,736
|
2,310
|
1,032
|
1,378
|
-
|
-
|
Enterprise Value (EV)
1 |
8,186
|
2,499
|
1,140
|
1,556
|
1,486
|
1,281
|
P/E ratio
|
-13.3
x
|
-4.99
x
|
-0.71
x
|
-5.95
x
|
-12.5
x
|
-76.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.1
x
|
3.68
x
|
1.65
x
|
1.76
x
|
1.59
x
|
1.44
x
|
EV / Revenue
|
16
x
|
3.98
x
|
1.82
x
|
1.98
x
|
1.72
x
|
1.34
x
|
EV / EBITDA
|
201
x
|
52
x
|
18.5
x
|
26
x
|
16.3
x
|
9.2
x
|
EV / FCF
|
-97.9
x
|
-11.8
x
|
-88.4
x
|
-19.8
x
|
66.8
x
|
18.3
x
|
FCF Yield
|
-1.02%
|
-8.46%
|
-1.13%
|
-5.06%
|
1.5%
|
5.46%
|
Price to Book
|
-
|
-
|
-
|
0.52
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
464,038
|
514,375
|
618,008
|
774,029
|
-
|
-
|
Reference price
2 |
16.67
|
4.490
|
1.670
|
1.780
|
1.780
|
1.780
|
Announcement Date
|
7/28/21
|
7/28/22
|
7/26/23
|
-
|
-
|
-
|
Fiscal Period: Mayo |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
179.6
|
406.6
|
513.1
|
628.4
|
627.1
|
783.8
|
865.2
|
953.9
|
EBITDA
1 |
-20.99
|
12.9
|
40.77
|
48.05
|
61.48
|
59.92
|
91.16
|
139.3
|
EBIT
1 |
-109.9
|
-49.44
|
-132.2
|
-142.5
|
-108.3
|
-158.2
|
-107.9
|
-47.24
|
Operating Margin
|
-61.22%
|
-12.16%
|
-25.76%
|
-22.68%
|
-17.26%
|
-20.18%
|
-12.47%
|
-4.95%
|
Earnings before Tax (EBT)
1 |
-11.85
|
-60.41
|
-345
|
-440.7
|
-1,450
|
-198.5
|
-87.54
|
-20.15
|
Net income
1 |
-12.5
|
-63.34
|
-336
|
-434.1
|
-1,443
|
-211.4
|
-86.3
|
-27.32
|
Net margin
|
-6.96%
|
-15.58%
|
-65.49%
|
-69.09%
|
-230.1%
|
-26.97%
|
-9.97%
|
-2.86%
|
EPS
2 |
-
|
-
|
-1.250
|
-0.9000
|
-2.350
|
-0.2990
|
-0.1425
|
-0.0233
|
Free Cash Flow
1 |
-198.1
|
-199.2
|
-83.59
|
-211.3
|
-12.89
|
-78.72
|
22.24
|
69.94
|
FCF margin
|
-110.32%
|
-48.99%
|
-16.29%
|
-33.63%
|
-2.06%
|
-10.04%
|
2.57%
|
7.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
24.39%
|
50.21%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/1/19
|
7/29/20
|
7/28/21
|
7/28/22
|
7/26/23
|
-
|
-
|
-
|
Fiscal Period: May |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
155.2
|
151.9
|
153.3
|
153.2
|
144.1
|
145.6
|
184.2
|
176.9
|
193.8
|
188.3
|
225.1
|
210.4
|
211.1
|
198.6
|
233.9
|
EBITDA
1 |
13.76
|
10.09
|
11.5
|
13.53
|
11.71
|
14.02
|
22.22
|
11.43
|
10.09
|
10.15
|
28.06
|
17.68
|
18.32
|
17.68
|
31.81
|
EBIT
1 |
-31.96
|
-36.29
|
-38.23
|
-20.97
|
-32.55
|
-29.38
|
-16.6
|
-34.36
|
-41.76
|
-82.1
|
-14.19
|
-23.73
|
-23.27
|
-21.64
|
-11.8
|
Operating Margin
|
-20.6%
|
-23.89%
|
-24.94%
|
-13.69%
|
-22.58%
|
-20.18%
|
-9.01%
|
-19.42%
|
-21.55%
|
-43.59%
|
-6.3%
|
-11.28%
|
-11.02%
|
-10.89%
|
-5.04%
|
Earnings before Tax (EBT)
1 |
0.126
|
50.64
|
-461.6
|
-58.58
|
-73.35
|
-1,207
|
-111.7
|
-48.6
|
-49.56
|
-107.9
|
-23.7
|
-33.9
|
-33.11
|
-30.3
|
-21.89
|
Net income
1 |
-0.201
|
43.19
|
-457.8
|
-65.79
|
-61.64
|
-1,196
|
-119.8
|
-55.86
|
-46.18
|
-105
|
-23.07
|
-32.96
|
-31.91
|
-29.2
|
-21.39
|
Net margin
|
-0.13%
|
28.44%
|
-298.58%
|
-42.94%
|
-42.76%
|
-821.32%
|
-65.05%
|
-31.57%
|
-23.83%
|
-55.74%
|
-10.25%
|
-15.66%
|
-15.12%
|
-14.7%
|
-9.15%
|
EPS
2 |
-
|
0.0900
|
-0.9000
|
-0.1300
|
-0.1100
|
-1.900
|
-0.1500
|
-0.1000
|
-0.0700
|
-0.1200
|
-0.0333
|
-0.0525
|
-0.0500
|
-0.0500
|
-0.0375
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/10/22
|
4/6/22
|
7/28/22
|
10/7/22
|
1/9/23
|
4/10/23
|
7/26/23
|
10/4/23
|
1/9/24
|
4/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: May |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
450
|
190
|
108
|
178
|
109
|
-
|
Net Cash position
1 |
62.4
|
66.1
|
-
|
-
|
-
|
-
|
-
|
96.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
11.04
x
|
3.952
x
|
1.754
x
|
2.971
x
|
1.19
x
|
-
|
Free Cash Flow
1 |
-198
|
-199
|
-83.6
|
-211
|
-12.9
|
-78.7
|
22.2
|
69.9
|
ROE (net income / shareholders' equity)
|
-1.15%
|
-4.81%
|
-11.8%
|
-3.35%
|
-37.4%
|
-6.3%
|
-2.3%
|
-0.4%
|
ROA (Net income/ Total Assets)
|
-
|
-2.96%
|
-8.66%
|
-2.59%
|
-29.6%
|
-4.8%
|
-1.8%
|
-0.3%
|
Assets
1 |
-
|
2,140
|
3,882
|
16,775
|
4,878
|
4,404
|
4,795
|
9,106
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
-
|
3.440
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-0.1700
|
-0.3700
|
0.0100
|
-0.0200
|
0.0700
|
0.1100
|
Capex
1 |
156
|
99.1
|
38.9
|
34.1
|
20.8
|
24.1
|
23.6
|
26.8
|
Capex / Sales
|
86.86%
|
24.37%
|
7.58%
|
5.42%
|
3.32%
|
3.08%
|
2.73%
|
2.81%
|
Announcement Date
|
8/1/19
|
7/29/20
|
7/28/21
|
7/28/22
|
7/26/23
|
-
|
-
|
-
|
Last Close Price
1.78
USD Average target price
2.375
USD Spread / Average Target +33.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.61% | 1.38B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|